▶주메뉴 바로가기
▶본문 바로가기
Celltrion in May established Celltrion Biopharma, its first unit in Ireland, for further expansion in the European biosimilar market, according to industry sources on Aug. 20. At the new unit, the ...
South Korean bio company OliPass has decided to inject 1.2 billion won ($988,000) to establish a unit in the US, according to industry sources on Aug 12. The company hopes to further strengthen its ...
Korean pharmaceutical company Yuhan announced on Aug. 7 that it has established new unit in Australia to expand its presence further globally. “We established Yuhan ANZ in Australia to focus more on...
SillaJen shares bottomed out on Aug. 2 on news that the global phase 3 clinical trials of its signature liver cancer treatment Pexa-Vec are likely to be suspended. The biotech firm trading on South...
Celltrion announced on Aug. 1 that it had started a phase 3 clinical trial of its new drug Remsima SC in the US. Remsima SC is a subcutaneous version of Remsima, the Korean company’s biosimilar of J...
South Korean pharmaceutical firm Samsung Bioepis said on July 24 it has won approval from the US Food and Drug Administration to sell one of its biosimilars in the United States. Hadlima, referen...
The value of stocks owned by both former and current entertainment agency owners in South Korea dropped nearly 30 percent compared to last year, data showed on July 21, as the industry is struggling ...
Three-dimensional printing of human organs is not some far-fetched fiction. Active research of the relevant technologies has gained pace around the globe, especially here in South Korea, where the ac...
South Korean biopharma firms Chong Kun Dang and Dong-A ST expect to launch their biosimilars in Japan without a headwind, despite escalating trade strife, as their drugs will be represented by Ja...
Celltrion announced July 19 that it has established the joint venture Vcell Healthcare in Shanghai with Hong Kong-based conglomerate Nan Fung Group to make a foray into China. Established in 1954, N...
HanAll Biopharma , a subsidiary of Daewoong Pharmaceutical, invested 5.6 billion won ($4.76 million) in Switzerland-based biotech startup Roivant Sciences’ subsidiary Immunovant Sciences, according ...
Korean biotech firm Bridge Biotherapeutics announced on July 18 that it has signed a contract with German-based pharmaceutical company Boehringer Ingelheim to license out its drug candidate BBT-877. ...
The prosecution has requested arrest warrants for Kim Tae-han, CEO of contract drug manufacturer Samsung BioLogics, and two other executives, surnamed Kim and Shim. The Seoul Central District Court ...
Kim Tae-han, president and CEO of contract drug manufacturer Samsung BioLogics, appeared again before prosecutors on July 5 to be questioned about whether he abetted the destruction of evidence in an...
South Korea’s drug authorities on July 3 revoked the permit for gene therapy drug Invossa for mislabeling and the false reporting of an ingredient used. The Ministry of Food and Drug Safety said ...
Genexine, ToolGen cancel merger plan on shareholder opposition
How can startups rise as driving force behind Korean economy?
Celltrion establishes Irish unit to expand in European biosimilar market
Korea Kolmar expands in Vietnam
Investors risk losing W127b on crashing German bond yields
5G adds connectivity to baseball
Raising the bar of ethical farming, startup offers ‘disruptive’ agritech
IBK to launch Indonesian unit in September
August 20, 2019
